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Metabolomics – a novel window into inflammatory
disease
Martin A. Fitzpatrick, Stephen P. Young
Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, United Kingdom
Summary
Inflammation is an important component of normal re-
sponses to infection and injury. However, chronic activa-
tion of the immune system, due to aberrant responses to
normal stimuli, can lead to the establishment of a per-
sistent inflammatory state. Such inflammatory conditions
are often debilitating, and are associated with a number of
important co-morbidities including cardiovascular disease.
Resting non-proliferative tissues have distinctive metabol-
ic activities and requirements, which differ considerably
from those in infiltrating immune cells, which are undergo-
ing proliferation and differentiation. Immune responses in
tissues may therefore be modulated by the relative abund-
ance of substrates in the inflamed site. In turn immune cell
activity can feed back and affect metabolic behaviour of
the tissues, as most clearly demonstrated in cachexia – the
loss of cellular mass driven by tumour necrosis factor-al-
pha (TNF-α) a key mediator of the inflammatory response.
Here we discuss the potential for metabolomic analysis to
clarify the interactions between inflammation and metabol-
ic changes underlying many diseases. We suggest that an
increased understanding of the interaction between inflam-
mation and cellular metabolism, energy substrate use, tis-
sue breakdown markers, the microbiome and drug meta-
bolites, may provide novel insight into the regulation of
inflammatory diseases.
Key words: inflammation; metabolomics; rheumatoid
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Metabolism and inflammation
Inflammation is a normal and important response to in-
fection and injury. The cardinal features of inflammation
– swelling, redness, stiffness and increased temperature –
are outward indicators of significant local changes in meta-
bolism. Increasing blood flow in turn affects local nutrient
supply and in particular oxygenation of the tissues while
infiltrating activated immune cells bring additional meta-
bolic stressors that must be met. Furthermore, inflamma-
tion is associated with the rapid influx, differentiation and
proliferation of leukocytes. Infiltrating cells have distinct
metabolic requirements and, together with the increased
cell number, result in a significant alteration in the metabol-
ic profile of the inflamed tissues. In turn, the environment
of the tissues may alter the activity, behaviour or differen-
tiation of the invading cells. The activity of macrophages
and neutrophils in both clearance of infection and tissue re-
pair is particularly significant due to the production of cy-
tokines and cytotoxic molecules, including reactive oxygen
species and reactive nitrogen species, consuming consider-
able oxygen, adenosine 5’-triphosphate (ATP) and reduced
nicotinamide adenine dinucleotide phosphate (NADPH) in
the process. Reactive species, while essential for killing in-
vading organisms, also put considerable stress on surround-
ing and distal tissues via loss of protective metabolites in-
cluding reduced glutathione (GSH). In rheumatoid arthritis
patients blood levels of GSH decline by 50% and this is
associated with a 3-fold increase in lipid peroxides [1]. A
similar picture is seen in healthy ageing and this is en-
Figure 1
Levels of plasma antioxidant glutathione decrease with age
whereas markers of oxidative damage lipid hydroperoxides
increase.
This provides an example of the magnitude of changes in
metabolite levels that can be observed in humans which, in this
case, may be consequence of inflammaging. Adapted from Nuttall
SL, Martin U, Sinclair AJ, Kendall MJ. Glutathione: in sickness and
in health. Lancet. 1998;351(9103):645–6 [62].
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hanced in individuals receiving medical attention (fig. 1)
suggesting that the process of “inflamma ging” may inter-
act with pathological developments to promote changes in
metabolism [2].
It is interesting to note that mechanisms of metabolic and
immune control co-evolved, originating in single fat body
organ as still seen in Drosophila melanogaster [3]. This as-
sociation persists in higher organisms, where lymph nodes
are embedded in perinodal adipose tissue that may influ-
ence immune responses [4]. In humans adipose tissue is
well infiltrated with macrophages, and the production of
inflammatory cytokines by both adipocytes and macro-
phages contributes to systemic inflammation [5]. This link
between inflammation and metabolism is well demon-
strated in cachexia, where the loss of cellular mass is driven
by tumour necrosis factor-alpha (TNF-α) a mediator of the
inflammatory response [5, 6]. Under normal circumstances
acute inflammatory triggers are cleared or repaired rap-
idly, with subsequent homeostatic return. However, there
are a number of chronic inflammatory diseases where aber-
rant immune activation results in a persistent inflammatory
state. The metabolic consequences of chronic inflamma-
tion extend beyond the local site of disease, driving im-
portant co-morbidities including accelerated atherosclero-
sis and cardiovascular disease. Understanding of the meta-
bolic aspects may therefore be key to fully characterising
inflammatory disease. However, given the complexity of
the interlinking metabolic pathways in different organs, tis-
sues and cells a systems biology approach is needed to as-
sess and interpret these metabolic changes.
Principles of metabolomics
Metabolomics is a novel systems approach that can be used
to dissect the local and systemic metabolic consequences
of inflammation. Just as genomics studies the genetic basis
of phenotype, and transcriptomics and proteomics study
the products of these genes, metabolomics seeks to under-
stand the downstream effects caused by the action of these
proteins and enzymes in the context of energy and meta-
bolite consumption and regulation. A hypothesis-forming
approach, it is driven by the non-discriminant analysis of
the low molecular weight metabolite component of target
samples. The potential of metabolomics has shown promise
in the prediction and diagnosis of diseases including ulcer-
ative colitis, rheumatoid arthritis, multiple sclerosis (MS)
among others [7–9].
Metabolomic analysis starts with the acquisition of meta-
bolite data from samples. There are a number of variations
of techniques for this purpose, although the most com-
monly used are nuclear magnetic resonance (NMR) spec-
troscopy, or mass spectrometry (MS). Samples may be de-
rived from any sample suitably processed to be cell-free,
including urines, plasma, cerebrospinal fluid, faecal ex-
tracts and synovial fluid [7–9], and pH stable through ad-
dition of buffers. Alternatively cell extracts may be per-
formed into a suitable solvent, such as methanol with chlo-
roform extraction to remove protein components. Consist-
ent processing and buffering is key to the success of meta-
bolomic analysis due to the potential confounding factors
that may result from variations in pH during acquisition –
including shifted peaks and chemical reaction resulting in
loss or gain of metabolites. Acquisition of samples results
in spectra containing a number of peaks, representing pro-
ton resonance in 1H NMR or mass/charge (m/z) ratios in
mass spectrometry. In practise however the goal of analys-
is is the same – using differences in metabolites to describe
the differences between sample groups. The large size of
the datasets and often numerous samples requires the use
of multivariate analysis to simplify and distil meaning from
the resulting data.
Statistical methods for the analysis of metabolomic data
may be broadly grouped into directed and undirected ap-
proaches [10]. In undirected analysis such as PCA, the
goal is to describe the maximum variation in the dataset it-
self without providing information to the model about the
class groupings. The output is a series of orthogonal prin-
cipal components, describing the maximum to minimum
variation in the data in turn through weighted peaks. If
the source of largest variation in the data is the difference
between control and test samples, principal components
analysis (PCA) alone is sufficient to differentiate class
Figure 2
Metabolomic analysis of serum samples from old ( ) and young (
) healthy volunteers.
1D spectra were acquired in a 500MHz spectrometer and
processed with NMRLab/Metabolab and analysed with partial least
squares discriminant analysis (PLS-DA). The two groups (<25 and
>75 years) were well separated on PLSDA (A) with loadings (B)
showing amine derivatives and ketone bodies are raised in ageing,
which may be markers of underlying inflammaging.
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groupings. However, in more variable samples, as is often
the case in biological sourced materials, other confounding
or random data may mask the true differences in the
samples. Here directed analysis techniques may be more
useful. Partial least squares regression (PLS) may be used
to describe variation in one dataset by reference to another
– for example, using metabolite concentrations to predict
disease activity, progression or severity. Similarly, the re-
lated technique PLS discriminant analysis (PLS-DA) uses
multivariate metabolomic peak data to describe the assign-
ment of samples to binary groups. By focusing on the vari-
ation that describes the differences between control and
test samples, it is possible to tease out the clinically relev-
ant variation in the face of significant unrelated noise. The
output of these approaches is markedly similar: a statist-
ical model from which is it possible to accurately predict
disease state or patient group from similarly processed
samples from new individuals. However, these models are
complicated and include multiple correlated peaks. For-
ward selection regression analysis may therefore be em-
ployed to iteratively discard peaks resulting in a small
number of metabolites while maintaining predictive capab-
ility – a requirement for the development of cheap specific
bioassays. Selection of controls, accounting for confound-
ing effects such as diet, smoking, and medication history, is
key to the development of accurate models.
A simple example of the output of a metabolomic study is
shown in figure 2, where we assessed NMR-derived meta-
bolic fingerprints of serum from a small cohort of healthy
elderly individuals (age >75 years) in comparison to young
donors (<25 years). The groups are clearly separated in a
PLS-DA model and analysis of the loadings plot (which
indicates which regions of the NMR spectra contribute to
the separation) indicates several distinguishing metabol-
ites including methylamine and ketone bodies which have
been associated with ageing in rats probably as a result in
changes in pyruvate and energy metabolism [11]. Ketone
bodies are also generated by inflammatory leukocytes and
have been observed in the synovium in RA [2]. Therefore,
here they may be present as a result of low grade inflam-
mation which is characteristic of inflammaging and so may
provide novel markers of this process [12].
By applying these metabolomics techniques to inflammat-
ory disease the goal is to determine the role of metabolic
processes in the development of normal and aberrant in-
flammatory states. Metabolite markers, assayed from the
various tissues and fluids, are accessible and simple to ob-
tain from patients while having the potential to provide
deeper indications of underlying disease processes.
Metabolic markers
In the following sections we take a systematic approach to
outline key markers identified by metabolomic studies to
date which are summarised in table 1.
In spite of the early state of the field, there already exist
a number of key areas of investigation where metabolic
patterns are emerging, both in general inflammatory dis-
ease and in specific pathologies. Here we focus on the most
important of these which include energy sources, hypoxia,
regulation of inflammation, tissue degradation, waste and
drug metabolites.
Table 1: Key metabolites and their association with inflammatory diseases in current literature arranged according to the major themes discussed.
Metabolite Associations Fluids Inflammatory diseases References
Lactate: Warburg and the hypoxic environment
Lactate Hypoxia, oxidative damage. SF, Urine, CSF RA, OA†, IIH, MS [8, 30, 32]
Citric acid cycle intermediates
Oxaloacetate CSF, VF IIH, LIU [9]
Citrate CSF IIH [9]
Malate Urine OA† [32]
Alternative energy sources
Amino acid metabolites
CD [48]Xanthurenic acid
Uracil, xanthine, glycine RA† [60]
Ketone bodies Acetyl-CoA, fatty acid, amino acid
breakdown.
SF, CSF RA, MS [12, 42, 43]
Lipoprotein-associated fatty acids Resting energy source SF, Blood IA, OA [41]
Tissue degradation and waste
Essential amino acids Protein breakdown Serum OA [46]
Hyaluronic acid
Trimethylamine Urine IBD, IBD†, CD [47, 53]
Urea VF LIU [52]
Xenobiotics and the Microbiome
Oxylipids NSAIDs [54, 61]
Cholesterol esters and Phospholipid metabolites Simvastatin [55]
Acetate Faecal CD [47]
Butyrate Faecal CD, T1D [47, 58]
Formate Urine CD [47]
Others
Creatinine CSF MS [30]
RA = rheumatoid arthritis; IA = inflammatory arthritis; OA = osteoarthritis; IIH = idiopathic intercranial hypertension; MS = multiple sclerosis; LIU = lens induced uveitis; CD
= Crohn’s disease. CSF = cerebospinal fluid, VF = vitreous fluid, SF = synovial fluid; † animal model.
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Lactate: the Warburg effect and
hypoxia
In the presence of adequate oxygen, differentiated cells
metabolise glucose through mitochondrial oxidation of gly-
colytic pyruvate in the tricarboxylic acid (TCA) cycle, with
resulting NADH fuelling oxidative phosphorylation to pro-
duce 36 ATP per glucose molecule. Under hypoxic condi-
tions the oxidative pathways are inhibited and glycolytic
pyruvate is instead excreted as lactate, with a decreased 2
ATP output per glucose molecules in the cell. Physiolo-
gical levels of oxygen range between 5%–12% depending
on tissue location. Structures in the body held naturally at
the lower end of this range, by virtue of low perfusion or
vascularisation, include the lymph nodes, eye and synovi-
um. In normal inflammatory conditions hypoxia results as
a side effect of blood vessel occlusion due to inflamma-
tion or as a result of increased cell density following infilt-
ration. Hypoxia is a key driver of cell migration into the
tissues and perfusion may act as a signalling mechanism
to invading cells [13]. Reductions in oxygen lead to sta-
bilisation of transcription factor hypoxia-inducible factor
(HIF) providing an elegant cellular oxygen detection sys-
tem. Stabilisation of HIF drives major changes in cellular
gene expression including the promotion of glycolytic en-
zymes. Peripheral blood CD4+ T cells exposed to hypox-
ia show dramatic induction of genes involved in metabol-
ism and homeostasis [14]. Innate immune cells, including
neutrophils and macrophages are thought better adapted to
function at low oxygen tensions with preferential use of
glycolysis to provide ATP even under normal physiological
oxygen [15]. Macrophages tend to accumulate in the hyp-
oxic sites of chronic inflammation and hypoxia is associ-
ated with the activation of infiltrating and tissue-resident
macrophages resulting in up-regulation of pro-inflammat-
ory IL-1, IL-6, IFN-γ and TNF-α [16–20]. Most infec-
tions or injuries are cleared or repaired quickly with perfu-
sion and metabolic homeostasis soon restored. However, in
poorly perfused tissues such as the rheumatoid synovium
and sclerotic tissues oxygen perfusion can fall as low as
0.5%–2.5% and this regulation may be perturbed leading to
continued recruitment [21, 22]. Lactate is a waste product
of normal metabolism reversibly converted from glycolytic
pyruvate via the enzyme lactate dehydrogenase. Excess
cellular lactate is excreted and re-circulated via conversion
in the live to glucose (the Cori cycle). In sufficiently oxy-
genated cells it may also be converted back to pyruvate
via reaction with intracellular NAD+ to fuel the citric acid
cycle. However, in poorly perfused tissues the production
of lactate outstrips this homeostatic control and lactate ac-
cumulates. In hypoxic conditions the HIF-mediated up-reg-
ulation of lactate dehydrogenase A further promotes this
accumulation [23].
Lactate therefore is a key marker of inflammatory sites un-
der hypoxia. However, this relationship is not restricted
to inflammation. In 1924 Otto Warburg first observed that
cancer cells metabolise glucose by glycolysis even under
aerobic conditions [24]. It has been suggested that that
all differentiating and replicating cells must use this same
mechanism in order to produce the requisite biomass for
cellular replication [25]. By this mechanism, glucose and
glutamine can adequately supply the majority of carbon,
nitrogen and energy for cell growth and division. Indeed,
under growth conditions, metabolising glucose to CO2 via
oxidative phosphorylation runs counter to the needs of the
cell. Therefore, non-proliferative, highly ATP-dependent
organs such as the brain favour free-energy production via
oxidative phosphorylation of glucose [26], while in con-
trast, under resting conditions, skeletal muscle metabolism
is predominantly fatty acid dependent, switching to glyco-
lysis and oxidative phosphorylation under activity [27]. In
proliferative tissues such as the lymph nodes, there is in-
stead a tendency towards metabolism of glucose to lact-
ate, pyruvate and CO2, and glutamine to ammonia, glutam-
ate and aspartate. Importantly this may also apply to cells,
such as polymorphonuclear leukocytes, that invade inflam-
matory sites [28, 29]. The switch to aerobic glycolysis
therefore compounds the production of lactate, locally and
distally – including where hypoxia is absent.
The role for lactate as a universal marker of inflammation
is borne out clinically. Increases in the ratio of lactate
: glucose in blood plasma and synovial fluid in patients
with rheumatoid arthritis has been shown to correlate with
active inflammation and oxidative damage to the joint,
for example [8]. Meanwhile, in a wide-ranging study of
cerebrospinal fluid (CSF) from patients with a number of
neurological conditions, high lactate was a distinguishing
feature of idiopathic intracranial hypertension (IIH) hinting
to a potential inflammatory basis for the disease with pres-
sure occlusion of the intracranial vasculature. Increased
CSF lactate and creatinine are also seen in multiple scleros-
is patients versus controls, potentially reflecting leukocyte
infiltration into the lesions [30]. Such alterations in pyr-
uvate and lactate can in turn drive downstream effects on
the citric acid cycle. Pyruvate may be converted to interme-
diates of the citric acid cycle, malate and oxaloacetate [31]
by pyruvate carboxylase and malic enzyme respectively.
Raised urine malate is a strong predictor of disease activ-
ity in the Hartley guinea pig model of OA [32]. Raised ox-
aloacetate and reduced citrate are also associated with dis-
ease in idiopathic intracranial hypertension together with
increases in ketone bodies 3-hydroxybutyrate, suggestive
of an anaerobic carbohydrate-deficient environment [9].
Alternative energy sources
The base relationship between resting energy expenditure
and body mass is described by the Kleiber formula (REE
= 293M0.75). Organ-specific metabolic rates and preferred
substrates are also well established (fig. 3) with the heart
and kidney consuming the major proportion of energy in
the resting adult, followed by the brain and liver [33, 34].
However, these basal rates are significantly altered by mal-
nutrition, illness, smoking, and inflammation and changes
in substrate availability can have disproportionate effects
[34]. Recent work on a cohort of RA patients found that
their global basal metabolic rate (BMR) was 6,276 kJoules/
day, which was 8% higher that the value from a control
group. Importantly a group of RA patients who smoked had
a 20% higher BMR of 7,188 kJoules/day (fig. 4) [35]. This
indicates how large the effects of inflammation and factors
promoting it can be and explains why changes in blood and
Review article: Medical intelligence Swiss Med Wkly. 2013;143:w13743
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tissue metabolites are easily observed. Inflammation is a
highly energy-dependent process and acutely reliant on ad-
equate energy availability to function correctly [36]. Fever
is associated with an 11% increase in energy consumption
per 1°C, while phagocyte production during an infectious
episode consumes approximately 790 kJoules [37, 38]. In
sepsis the metabolic rate can reach up to 30%–60% above
baseline levels [39]. The converse is also true, with the en-
ergy surplus associated with obesity and other metabolic
syndromes driving altered immune responses and chronic
inflammation [40].
Energy availability is therefore a key regulator of immune
activation and resolution. Resting energy requirements for
non-brain and non-proliferative tissues, particularly the
skeletal muscle and heart, are predominantly met by the
Figure 3
Metabolic requirements of the major tissues.
While the overall resting energy expenditure falls in old age, relative
contributions of organs to the total remains stable. Adapted from
Wang Z, Ying Z, Bosy-Westphal A, Zhang J, Schautz B, Later W, et
al. Specific metabolic rates of major organs and tissues across
adulthood : evaluation by mechanistic model of resting energy
expenditure 1–4. Am J Clin Nutr. 2010;92(4):1369–77 [34].
Figure 4
Smoking has a significant effect on the basal metabolic rate of
rheumatoid arthritis patients (RA).
Metabolic rate is higher in RA compared to healthy controls and this
is enhanced even further by smoking, indicating the complexity of
interactions between metabolism and disease. Adapted from
Metsios GS, Stavropoulos-Kalinoglou A, Nevill M, Douglas KMJ,
Koutedakis Y, Kitas GD. Cigarette smoking significantly increases
basal metabolic rate in patients with rheumatoid arthritis. Ann
Rheum Dis. 2008;67(1):70–3 [35].
oxidation of free fatty acids [27]. Due to the oxidation re-
quirement their use is typically limited to well-perfused tis-
sues, however damage to the joint in inflammatory and os-
teoarthritis appears to be associated with an increased per-
fusion of macromolecular fatty acids into the synovium. In
osteoarthritis increased lipoprotein associated fatty acids,
together with metabolism products glycerol, ketones and
pyruvate, are all indicative of lipolysis occurring as an
energy source. Similarly, a study of RA synovial fluid
samples has shown reduced chylomicron and very-low-
density-lipoprotein associated triglycerides compared to
controls, suggesting increased utilisation of fats as an en-
ergy source in the joint in spite of the hypoxic environment.
Blood plasma levels of cholesterol, acetylated glycoprotein
and lipids were also raised in RA [41].
Fatty acids are additionally broken down in the liver and
kidney, producing ketone bodies for recirculation to the
tissues. Ketone bodies acetoacetate and 3-hydroxybutyrate
provide a key energy source for the heart and brain, through
reconversion to acetyl-CoA to feed the citric acid cycle in
the tissues, while acetone is readily excreted as waste. In
normal fasting conditions plasma levels of ketone bodies
are low, as tissues with lower metabolic needs sustain
themselves on local reserves of fatty acids, but these
sources are not sufficient for active, highly energy-depend-
ent tissues and ketone body production rises significantly.
After 3.5 days of glucose starvation the brain can obtain
as much as 25% of total energy from ketone bodies [26].
However, alterations in ketone body production and meta-
bolism have also been observed in inflammatory diseases
in the absence of glucose restriction. Elevated
3-hydroxybutyrate has also been seen in MS with samples
containing as much as 32 μM concentration of this meta-
bolite [42, 43]. As previously described, chronic inflam-
mation may drive metabolic changes, deriving in particular
from cachexia-associated catabolism and ketogenesis. The
presence of the ketone body 3-hydroxybutyrate in urine
has been linked to respiratory chain deficiency leading
to impaired NADH oxidation [44]. Local changes may
also be informative: raised synovial fluid concentrations of
ketone bodies, particularly 3-hydroxybutyrate, in patients
with rheumatoid arthritis are suggested to reflect the de-
gradation of local acetyl-CoA under hypoxic conditions
[12]. This was also suggested by the low glucose NMR sig-
nal in synovial fluid which was 20% lower than paired sera,
which is a direct measure of the decrease in this metabolite.
Tissue degradation and waste
Normal tissue homeostasis requires the turnover of both
cellular and acellular biomass. In the inflammatory state
however, these processes are often altered offering the pos-
sibility of characteristic excess or paucity of specific bio-
markers. Specific tissue-derived metabolites may provide
the clearest markers of gross tissue destruction. Hyaluronic
acid for example, is a major component of articular cartil-
age proteoglycan aggregate and essential for the function-
al integrity of extracellular matrix. Hyaluronidase activity
is absent in both normal and inflamed synovial fluid, and
therefore breakdown does not occur. However, in rheum-
atoid arthritis the action of reactive oxygen species results
Review article: Medical intelligence Swiss Med Wkly. 2013;143:w13743
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in detectable levels of hyaluronic acid in the synovium
providing a direct local marker of joint destruction [45].
Essential amino acids, those that cannot be synthesised de
novo in the human body, also offer a useful general mark-
er for protein degradation. On a background of steady diet-
ary intake any alterations in tissue concentrations must de-
rive from catabolism of existing proteins – sourced from
gross tissue destruction, apoptosis or cellular autophagy.
This principle has been clearly demonstrated in a mass
spectrometry study of serum from patients with OA. Valine
concentration in the OA patients was 306 μM while in the
control group it was 266 μM, giving rise to a significant
alteration in the ratio of serum valine to histidine and leu-
cine to histidine in patients versus controls [46]. In a study
of comparing faecal extracts from patients with ulcerative
colitis (UD) and Crohn’s disease (CD), higher levels of
alanine, isoleucine, leucine, lysine and valine were all seen
in patients with CD [47]. Gas chromatography-mass spec-
trometry analysis of urinary metabolites in a mouse model
of Crohn’s disease similarly identified alterations in trypto-
phan metabolism [48]. This appears to be a general feature
of inflammatory processes, as demonstrated using adenov-
iral vector to induce chronic expression of inflammatory
IL-1B or TNFα, the IL-1B treated group similarly saw in-
creases in leucine, isoleucine, valine, n-butyrate and gluc-
ose [49]. Interestingly, dietary supplementation with a sub-
set of essential amino acids, the branch chain amino acids,
has shown to drive an increase in Th1-like responses via
IL-1, IL-2, TNF and interferon suggesting the possibility of
a link between local release from degradation and chronic
inflammation [50].
The catabolism of amino acids, either as an energy source
or resulting from protein degradation, results in the local
and systemic accumulation of ammonia. This toxic meta-
bolite is rapidly converted to urea, predominantly in the liv-
er and kidney but also elsewhere, for subsequent excretion
via urine [51]. In tissue destruction other nitrogenous base
carriers, such as trimethylamine, perform broadly similar
functions. Excretion of nitrogenous waste is key to tissue
homeostasis, however, under excess production or in sites
of poor circulation these metabolites can accumulate. For
example in a study of ocular inflammatory diseases com-
pared vitreous humour samples from patients with vari-
ous retinal disorders distinctions could be drawn with urea,
oxaloacetate and glucose all significantly raised in lens-
induced uveitis (LIU) compared to chronic non-infectious
uveitis (CU) [52]. Similarly, a study of urinary metabol-
ites in a IL-10 deficient mouse model of inflammatory
bowel disease (IBD) showed an increase in trimethylam-
ine (TMA) compared to controls, with the increase in urine
TMA (1540 μM in the IL10 deficient compared to 308
μM in the wild-type at 20 weeks) running parallel to the
progression of IBD [53], a finding corroborated in human
studies using both urine and faecal extracts [47].
Xenobiotics and the microbiome
So far we have dealt only with metabolites of human biolo-
gical origin. However, two other broad metabolite classes
deserve further mention in the context of inflammatory dis-
ease: xenobiotics and the microbiome.
Xenobiotics are chemicals found in an organism that are
not derived from normal biological processes or dietary in-
take – a classification that includes most drug treatments.
Metabolism of xenobiotics is a complex process, predom-
inantly occurring in the liver and typically involving mul-
tiple steps of oxidation, reduction, hydrolysis, cyclisation,
and decyclisation with the end goal of detoxification and
excretion. Metabolism is associated with characteristic pro-
file of intermediates and excretion products that are unique
to the drug or class. In a clinical context these metabolites
simply restate what is already known – the treatment regi-
men of the patient. More interesting are the effects of drug
metabolism on disease progression and resolution. For ex-
ample, in a study of diclofenac significantly altered levels
of oxylipids were seen in those patients that responded to
the drug, with arachadonic acid metabolite 5,6-DHET iden-
tified as a novel marker of inflammation [54]. Similarly,
analysis of patient responses to simvastatin successfully
discriminated responders and non-responders by metabol-
ic profiles of cholesterol esters and phospholipid metabol-
ites [55]. Interestingly, this study was also able to discrim-
inate between metabolites associated with drug effects on
LDL-C or C-reactive protein independently – character-
ising mechanism of action within an individual. Potentially,
the baseline metabolic characteristics of an individual may
have important implications for drug lifetime, and effect-
iveness, and provide a route to tailoring dosing or drug
choice to an individual in accordance to not just genetic
variability but also lifestyle and diet.
The microbiome is a collective term for the totality of com-
mensal bacteria within our bodies. Bacteria outnumber our
own cells by a ratio of 10 to 1 [56], are responsible for
many essential metabolic processes for our health, and re-
spond to both inflammatory and immune processes. In an
analysis of faecal extracts from patients with Crohn’s dis-
ease (CD) and ulcerative colitis (UC) reduced levels of bu-
tyrate, acetate, methylamine and TMA were detected com-
pared to controls [47]. Urinary metabolites derived from
alterations in gut metabolism also allow distinction to be
drawn between the two diseases with hippurate and
4-cresol low in CD versus UC and controls, and formate
higher in CD [57]. While it is perhaps unsurprising that in-
flammatory gut conditions would drive alterations in gut
bacterial metabolism, changes have also been seen in other
conditions with no known gut involvement. In a case-con-
trol study of type-1 diabetes a switch in gut bacteria from
mucin-degrading, butyrate producing bacteria, to non-bu-
tyrate and lactate-utilising bacteria has been associated
with development of the disease [58]. The role of the mi-
crobiome in cardiovascular conditions was likewise
demonstrated by the finding that metabolism of dietary le-
cithin by gut flora leads to absorption and accumulation of
derivatives of choline which in turn promotes disease [59].
This close relationship between the metabolism of gut bac-
teria and elsewhere in the body provides a key challenge in
our understanding of disease processes through analysis of
body fluids.
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Conclusion
Metabolomics is, a novel systems approach offering insight
into the underlying mechanisms of inflammatory disease.
As outlined here, seemingly disparate metabolic markers
can be broadly arranged into functional groupings that to-
gether describe local and global disease processes. The key
difficulty is in separating these local and global effects
when assaying through a single bio-fluid. However, in the
context of diagnostic or prognostic markers, this is not
necessarily required. Metabolic processes do not occur in
isolation, and through the noise the interaction of the mul-
tiple systems involved in an inflammatory response
emerges a characteristic fingerprint of disease. In develop-
ing diagnostic assays we are aided by the fact that these
fingerprints frequently consist of the same relatively small
subset of metabolites, yet maintain their discriminative ca-
pacity, sensitivity and specificity. Metabolomics offers a
novel non-invasive approach to rapid diagnosis, prognosis
and prediction of inflammatory disease outcomes.
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Figures (large format)
Figure 1
Levels of plasma antioxidant glutathione decresae with age whereas markers of oxidative damage lipid hydroperoxides increase.
This provides an example of the magnitude of changes in metabolite levels that can be observed in humans which, in the case, may be
consequence of inflammaging. Adapted from Nuttall SL, Martin U, Sinclair AJ, Kendall MJ. Glutathione: in sickness and in health. Lancet.
1998;351(9103):645–6 [62].
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Figure 2
Metabolomic analysis of serum samples from old ( ) and young ( ) healthy volunteers.
1D spectra were acquired in a 500MHz spectrometer and processed with NMRLab/Metabolab and analysed with partial least squares
discriminant analysis (PLS-DA). The two groups (<25 and >75 years) were well separated on PLSDA (A) with loadings (B) showing amine
derivatives and ketone bodies are raised in ageing, which may be markers of underlying inflammaging.
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Figure 3
Metabolic requirements of the major tissues.
While the overall resting energy expenditure falls in old age, relative contributions of organs to the total remains stable. Adapted from Wang Z,
Ying Z, Bosy-Westphal A, Zhang J, Schautz B, Later W, et al. Specific metabolic rates of major organs and tissues across adulthood : evaluation
by mechanistic model of resting energy expenditure 1–4. Am J Clin Nutr. 2010;92(4):1369–77 [34].
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Figure 4
Smoking has a significant effect on the basal metabolic rate of rheumatoid arthritis patients (RA).
Metabolic rate is higher in RA compared to healthy controls and this is enhanced even further by smoking, indicating the complexity of
interactions between metabolism and disease. Adapted from Metsios GS, Stavropoulos-Kalinoglou A, Nevill M, Douglas KMJ, Koutedakis Y,
Kitas GD. Cigarette smoking significantly increases basal metabolic rate in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(1):70–3
[35].
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